甲状腺癌内科治疗进展

doi:10.3760/cma.j.cn371439-20200224-00008

摘要/Abstract

摘要：

甲状腺癌作为一种常见的头颈部和内分泌系统恶性肿瘤,具有高发病率和低死亡率的特点。但临床上对于晚期或高风险甲状腺癌患者的治疗仍是一个难题。目前,对甲状腺癌分子发病机制的深入研究为甲状腺癌的化疗、分子靶向治疗、免疫治疗提供了新的机遇。

Abstract:

Thyroid cancer is a common malignant tumor of the head and neck and endocrine system, characterized by high morbidity and low mortality. The main clinical challenge is the treatment of patients with advanced or high-risk thyroid cancer. At present, the study on the molecular pathogenesis of thyroid cancer provide new opportunities for thyroid cancer, including chemotherapy, molecular targeted therapy and immunotherapy.

Key words: Thyroid neoplasms, Drug therapy, Molecular targeted therapy, Immunotherapy

王家乐, 曹君. 甲状腺癌内科治疗进展[J]. 国际肿瘤学杂志, 2020, 47(4): 231-235.

Wang Jiale, Cao Jun. Progress of medical treatment for thyroid cancer[J]. Journal of International Oncology, 2020, 47(4): 231-235.

参考文献 32

[1]	董方, 薛金才, 王云生 , 等. 甲状腺癌外照射放射治疗的变迁[J]. 国际肿瘤学杂志, 2019,46(11):641-648. DOI: 10.3760/cma.j.issn.1673-422X.2019.11.001.
[2]	Wiltshire JJ, Drake TM, Uttley L , et al. Systematic review of trends in the incidence rates of thyroid cancer[J]. Thyroid, 2016,26(11):1541-1552. DOI: 10.1089/thy.2016.0100. doi: 10.1089/thy.2016.0100
[3]	Grani G, Lamartina L, Durante C , et al. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management[J]. Lancet Diabetes Endocrinol, 2018,6(6):500-514. DOI: 10.1016/S2213-8587(17)30325-X. doi: 10.1016/S2213-8587(17)30325-X
[4]	Saini S, Tulla K, Maker AV , et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective[J]. Mol Cancer, 2018,17(1):154. DOI: 10.1186/s12943-018-0903-0. doi: 10.1186/s12943-018-0903-0
[5]	Valerio L, Pieruzzi L, Giani C , et al. Targeted therapy in thyroid cancer: state of the art[J]. Clin Oncol (R Coll Radiol), 2017,29(5):316-324. DOI: 10.1016/j.clon.2017.02.009. doi: 10.1016/j.clon.2017.02.009
[6]	Iyer PC, Dadu R, Ferrarotto R , et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma[J]. Thyroid, 2018,28(1):79-87. DOI: 10.1089/thy.2017.0285. doi: 10.1089/thy.2017.0285
[7]	Yang H, Chen Z, Wu M , et al. Remarkable response in 2 cases of advanced poorly differentiated thyroid carcinoma with liposomal doxorubicin plus cisplatin[J]. Cancer Biol Ther, 2016,17(6):693-697. DOI: 10.1080/15384047.2016.1167295. doi: 10.1080/15384047.2016.1167295
[8]	Beckham TH, Romesser PB, Groen AH , et al. Intensity-modulated radiation therapy with or without concurrent chemotherapy in nonanaplastic thyroid cancer with unresectable or gross residual disease[J]. Thyroid, 2018,28(9):1180-1189. DOI: 10.1089/thy.2018.0214. doi: 10.1089/thy.2018.0214
[9]	Milling RV, Grimm D, Kruger M , et al. Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension[J]. Int J Mol Sci, 2018, 19(10). pii: E3258. DOI: 10.3390/ijms19103258.
[10]	Naoum GE, Morkos M, Kim B , et al. Novel targeted therapies and immunotherapy for advanced thyroid cancers[J]. Mol Cancer, 2018,17(1):51. DOI: 10.1186/s12943-018-0786-0. doi: 10.1186/s12943-018-0786-0
[11]	Brose MS, Schlumbeger M, Jeffers M , et al. Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: subanalysis of the sorafenib phase Ⅲ DECISION trial[J]. Clin Cancer Res, 2019,25(24):7370-7380. DOI: 10.1158/1078-0432.CCR-18-3439. doi: 10.1158/1078-0432.CCR-18-3439
[12]	Ito Y, Onoda N, Ito KI , et al. Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma[J]. Thyroid, 2017,27(9):1142-1148. DOI: 10.1089/thy.2016.0621. doi: 10.1089/thy.2016.0621
[13]	Sherman EJ, Dunn LA, Ho AL , et al. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer[J]. Cancer, 2017,123(21):4114-4121. DOI: 10.1002/cncr.30861. doi: 10.1002/cncr.30861
[14]	Schlumberger M, Tahara M, Wirth LJ , et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015,372(7):621-630. DOI: 10.1056/NEJMoa1406470. doi: 10.1056/NEJMoa1406470
[15]	Brose MS, Worden FP, Newbold KL , et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase Ⅲ SELECT trial[J]. J Clin Oncol, 2017,35(23):2692-2699. DOI: 10.1200/JCO.2016.71.6472. doi: 10.1200/JCO.2016.71.6472
[16]	Oh HS, Shin DY, Kim M , et al. Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a Korean multicenter study[J]. Thyroid, 2019,29(12):1804-1810. DOI: 10.1089/thy.2019.0246. doi: 10.1089/thy.2019.0246
[17]	Kim SY, Kim SM, Chang HJ , et al. SoLAT (sorafenib lenvatinib alternating treatment): a new treatment protocol with alternating sorafenib and lenvatinib for refractory thyroid cancer[J]. BMC Cancer, 2018,18(1):956. DOI: 10.1186/s12885-018-4854-z. doi: 10.1186/s12885-018-4854-z
[18]	Tappenden P, Carroll C, Hamilton J , et al. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model[J]. Health Technol Assess, 2019,23(8):1-144. DOI: 10.3310/hta23080.
[19]	Fallahi P, Di Bari F, Ferrari SM , et al. Selective use of vandetanib in the treatment of thyroid cancer[J]. Drug Des Devel Ther, 2015,9:3459-3470. DOI: 10.2147/DDDT.S72495.
[20]	Hu MI, Elisei R, Dedecjus M , et al. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer[J]. Endocr Relat Cancer, 2019,26(2):241-250. DOI: 10.1530/ERC-18-0258.
[21]	Hadoux J, Schlumberger M . Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer[J]. Best Pract Res Clin Endocrinol Metab, 2017,31(3):335-347. DOI: 10.1016/j.beem.2017.04.009. doi: 10.1016/j.beem.2017.04.009
[22]	Schlumberger M, Elisei R, Müller S , et al. Overall survival analysis of EXAM, a phase Ⅲ trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma[J]. Ann Oncol, 2017,28(11):2813-2819. DOI: 10.1093/annonc/mdx479. doi: 10.1093/annonc/mdx479
[23]	Cabanillas ME, de Souza JA, Geyer S , et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase Ⅱ International Thyroid Oncology Group Trial[J]. J Clin Oncol, 2017,35(29):3315-3321. DOI: 10.1200/JCO.2017.73.0226. doi: 10.1200/JCO.2017.73.0226
[24]	Hyman DM, Puzanov I, Subbiah V , et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. N Engl J Med, 2015,373(8):726-736. DOI: 10.1056/NEJMoa1502309. doi: 10.1056/NEJMoa1502309
[25]	Brose MS, Cabanillas ME, Cohen EE , et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016,17(9):1272-1282. DOI: 10.1016/S1470-2045(16)30166-8. doi: 10.1016/S1470-2045(16)30166-8
[26]	Falchook GS, Millward M, Hong D , et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer[J]. Thyroid, 2015,25(1):71-77. DOI: 10.1089/thy.2014.0123. doi: 10.1089/thy.2014.0123
[27]	Subbiah V, Kreitman RJ, Wainberg ZA , et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer[J]. J Clin Oncol, 2018,36(1):7-13. DOI: 10.1200/JCO.2017.73.6785.
[28]	Ravaud A, de la Fouchardière C, Caron P , et al. A multicenter phase Ⅱ study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study[J]. Eur J Cancer, 2017,76:110-117. DOI: 10.1016/j.ejca.2017.01.029. doi: 10.1016/j.ejca.2017.01.029
[29]	Sun Y, Du F, Gao M , et al. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J]. Thyroid, 2018,28(11):1455-1461. DOI: 10.1089/thy.2018.0022. doi: 10.1089/thy.2018.0022
[30]	Shi X, Yu PC, Lei BW , et al. Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence/persistent disease in medullary thyroid carcinoma[J]. Thyroid, 2019,29(9):1269-1278. DOI: 10.1089/thy.2019.0079. doi: 10.1089/thy.2019.0079
[31]	Mehnert JM, Varga A, Brose MS , et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer[J]. BMC Cancer, 2019,19(1):196. DOI: 10.1186/s12885-019-5380-3. doi: 10.1186/s12885-019-5380-3
[32]	Iyer PC, Dadu R, Gule-Monroe M , et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma[J]. J Immunother Cancer, 2018,6(1):68. DOI: 10.1186/s40425-018-0378-y. doi: 10.1186/s40425-018-0378-y